Moleculin Biotech, Inc. ( MBRX ) shares are trading higher on Wednesday after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model.

What To Know: The preclinical data suggests that Annamycin effectively targets acute myeloid leukemia (AML) cell lines resistant to Cytarabine (Ara-C) and Venetoclax (VEN) in lab tests using cells from patients with advanced or relapsed AML.

“The preliminary clinical activity of Annamycin in heavily pretreated, relapsed/refractory AML patients who had progressive disease following Ara-C and VEN is very exciting and would provide a much needed treatment option for other patients who otherwise have very poor outcomes, said Giovanni Martinelli, Lead of the EU-funded IMPACT-AML program and Moleculin Scientific Advisory Board member.

The data comes from the company’s abstract titled, “Annamycin, a non-cardiotoxic anthracycline, demonstrates unique organotropism and activity against Ara-C and Venetoclax resistant AML,” presented at the American Society of Hematology (ASH) Annual Meeting held Dec. 7-10, in San Diego, CA.

The company is advancing Annamycin development with the Phase 3 MIRACLE trial (MB-108), evaluating Annamycin in combination with Cytarabine for the treatment of relapsed or refractory AML. This global trial, including sites in the United States, is set to begin patient treatment during the 2025 first quarter.

Related Link: Integral Ad Science Chief Financial Officer Trades $80K In Company Stock

MBRX Price Action: At the time of publication, Moleculin shares are trading 12% higher at $2.59, according to data from Benzinga Pro.

Image: Emilian Danaila from Pixabay